Markets:

Overview

News

Currencies

International

Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.655 +0.095 (+1.71%)

Streaming Delayed Price Updated: 2:46 PM EDT, Apr 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Savara, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Savara Announces Participation in Upcoming Healthcare Conferences

November 13, 2024

From Savara Inc.

Via Business Wire

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Savara Inc.

Via Business Wire

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

November 04, 2024

From Savara Inc.

Via Business Wire

SVRA Stock Earnings: Savara Misses EPS for Q2 2024 ↗

August 12, 2024

SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

SVRA Stock Earnings: Savara Misses EPS for Q1 2024 ↗

May 09, 2024

SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV

October 22, 2024

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

October 18, 2024

From Savara Inc.

Via Business Wire

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

October 01, 2024

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

September 27, 2024

From Savara Inc.

Via Business Wire

Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

September 27, 2024

From Savara Inc.

Via Business Wire

Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately

September 24, 2024

From Savara Inc.

Via Business Wire

Savara to Host Analyst and Investor Webinar on September 30, 2024

September 23, 2024

From Savara Inc.

Via Business Wire

Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

September 09, 2024

Via Benzinga

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024

September 08, 2024

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

September 06, 2024

From Savara Inc.

Via Business Wire

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 03, 2024

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

August 16, 2024

From Savara Inc.

Via Business Wire

Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024

August 15, 2024

From Savara Inc.

Via Business Wire

Savara Reports Second Quarter 2024 Financial Results and Provides Business Update

August 12, 2024

From Savara Inc.

Via Business Wire

Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock

June 28, 2024

From Savara Inc.

Via Business Wire

Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? ↗

June 26, 2024

Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

June 26, 2024

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!

Via InvestorPlace

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 26, 2024

From Savara Inc.

Via Business Wire

Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

June 25, 2024

From Savara Inc.

Via Business Wire

3 Penny Stocks Poised for Major Upside Over the Next 5 Years ↗

June 19, 2024

These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring.

Via InvestorPlace

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗

June 11, 2024

Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.

Via InvestorPlace

Savara to Present at the Jefferies Global Healthcare Conference

May 29, 2024

From Savara Inc.

Via Business Wire

Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

May 19, 2024

From Savara Inc.

Via Business Wire

Savara Announces New Employment Inducement Grant

May 16, 2024

From Savara Inc.

Via Business Wire

Savara Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024

From Savara Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.